The effect of a matrix metalloproteinase inhibitor on inflammation-mediated preterm delivery.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 17547891.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Several matrix metalloproteinases (MMP) have been implicated in preterm parturition. We hypothesized that administration of a MMP inhibitor would reduce the rate of inflammation-mediated preterm delivery and prolong gestation in a mouse model. We utilized an animal model of endotoxin-induced preterm delivery using timed pregnant C57Bl6 mice. Test animals received lipopolysaccharide (LPS) followed by the MMP inhibitor at 1 dose 12 hours after the LPS. Control mice received the same dose of LPS, followed by a control solution 12 hours after the LPS. The primary outcome was preterm delivery rate. Mice in the study group had a significantly lower rate of preterm delivery (44%) compared to 100% in the controls (P = .009). Furthermore, the latency between the administration of injection and delivery was also longer in the study group (means 28.3 hours, standard deviation 9.4 hours) than among controls (mean 15.7 hours, standard deviation 1.8 hours) (P < .001). Administration of an MMP inhibitor results in a decreased rate of inflammation-mediated preterm delivery in this animal model.
Medical subject headings
- Dipeptides
- Matrix Metalloproteinase Inhibitors
- Obstetric Labor, Premature
- Protease Inhibitors